Pharmacological suppression of the Ras/MAPK pathway in thyroid carcinoma cells can provoke opposite effects on cell migration and proliferation: The appearance of yin-yang effects and the need of combinatorial treatments

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2587-2595

  Glassmann, Alexander ^a   Winter, Jochen ^b   Kraus, Dominik ^c   Veit, Nadine ^d   Probstmeier, Rainer ^d  

^a Life Science Inkubator   (Germany)

^b Oral Cell Biology Group Department of Periodontology Operative and Preventive Dentistry   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Akt; ERK1 2; Migration; Proliferation; Small molecule kinase inhibitor; Thyroid cancer

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BENZAMIDE DERIVATIVE; DIPHENYLAMINE; FUSED HETEROCYCLIC RINGS; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANALOGS AND DERIVATIVES; CARCINOMA; CELL MOTION; CELL PROLIFERATION; CHINESE MEDICINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PATHOLOGY; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TUMOR CELL LINE;

BENZAMIDES; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DIPHENYLAMINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MAP KINASE SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; YIN-YANG;

EID: 84907703167     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2668     Document Type: Article

References (29)

1. Ambrosetti MC, Colato C, Dardano A, Monzani F and Ferdeghini M: Radioiodine ablation: when and how. Q J Nucl Med Mol Imaging 53:473-481, 2009.
2. Hannallah J, Rose J and Guerrero MA: Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma. Int J Endocrinol 2013:317487, 2013.
3. Dar AC and Shokat KM: The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu Rev Biochem 80:769-795, 2011.
4. Gild ML, Bullock M, Robinson BG and Clifton-Bligh R: Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 7:617-624, 2011.
5. Antonelli A, Fallahi P, Ferrari SM, et al: Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother 62:559-563, 2008.
6. Nikiforov YE: Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 21: S37-S43, 2008.
7. Saji M and Ringel MD: The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 32:20-28, 2010.
8. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140, 2008.
9. Duntas LH and Bernardini R: Sorafenib: rays of hope in thyroid cancer. Thyroid 2:1351-1358, 2010.
10. Fallahi P, Ferrari SM, Santini F, et al: Sorafenib and thyroid cancer. BioDrugs 27:615-628, 2013.
11. Chai H, Luo AZ, Weerasinghe P and Brown RE: Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. Int J Clin Exp Pathol 3:408-415, 2010.
12. Carlo-Stella C, Locatelli SL, Giacomini A, et al: Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells. PLoS One 8: e61603, 2013.
13. Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P and Grant S: Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leuk Res 34:379-386, 2010.
14. Rose A, Grandoch M, vom Dorp F, Rtibben H, Rosenkranz A, Fischer JW and Weber AA: Stimulatory effects of the multikinase inhibitor sorafenib on human bladder cancer cells. Br J Pharmacol 160:1690-1698, 2010.
15. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C and Evers BM: PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res 176:542-548, 2012.
16. Fremin C and Meloche S: From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 3: Feb. 11, 2010. doi: 10.1186/1756-8722-3-8.
17. Glassmann A, Reichmann K, Scheffler B, Glas M, Veit N and Probstmeier R: Pharmacological targeting of the constitutively activated MEK/MAPK-dependent signaling pathway in glioma cells inhibits cell proliferation and migration. Int J Oncol 39:1567-1575, 2011.
18. Mendoza MC, Er EE and Blenis J: The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36:320-328, 2011.
19. Kandil E, Tsumagari K, Ma J, et al: Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways. J Surg Res 184:898-906, 2013.
20. Hong SK, Jeong JH, Chan AM and Park JI: AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. Exp Cell Res 319:1732-1743, 2013.
21. Niba ET, Nagaya H, Kanno T, et al.: Crosstalk between PI3 kinase PDKl/Akt/Racl and Ras/Raf/MEK/ERK pathways downstream PDGF receptor. Cell Physiol Biochem 31:905-913, 2013.
22. Wang CC, Cirit M and Haugh JM: PI3K-dependent cross-talk interactions converge with Ras as quantifiable inputs integrated by Erk. Mol Syst Biol 5:246, 2009.
23. Meloche S and Pouyssegur J: The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the Gl- to S-phase transition. Oncogene 26:3227-3239, 2007.
24. Whalen AM, Galasinski SC, Shapiro PS, Nahreini TS and Ahn NG: Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol Cell Biol 17:1947-1958, 1997.
25. Chen H, Zhu G, Li Y, et al: Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res 69:9228-9235, 2009.
26. Huang C, Jacobson K and Schaller MD: MAP kinases and cell migration. J Cell Sci 117:4619-4628, 2004.
27. Knight ZA, Lin H and Shokat KM: Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10:130-137, 2010.
28. Jin N, Jiang T, Rosen DM, Nelkin BD and Ball DW: Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 94:4107-4112, 2009.
29. Liu D and Xing M: Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid 18:853-864, 2008.